BRPI0919827B8 - processos para aumentar o rendimento de uma reação de peguilação de r-methug-csf processo para a produção em escala grama de peg- r-methug-csf - Google Patents

processos para aumentar o rendimento de uma reação de peguilação de r-methug-csf processo para a produção em escala grama de peg- r-methug-csf

Info

Publication number
BRPI0919827B8
BRPI0919827B8 BRPI0919827A BRPI0919827A BRPI0919827B8 BR PI0919827 B8 BRPI0919827 B8 BR PI0919827B8 BR PI0919827 A BRPI0919827 A BR PI0919827A BR PI0919827 A BRPI0919827 A BR PI0919827A BR PI0919827 B8 BRPI0919827 B8 BR PI0919827B8
Authority
BR
Brazil
Prior art keywords
csf
methug
yield
increasing
peg
Prior art date
Application number
BRPI0919827A
Other languages
English (en)
Inventor
Khare Aruna
Shripati Pawar Digamber
Kumar Rana Dilip
Kumar Paliwal Dinesh
Lal Saksena Divya
Chandrakesan Muralidharan
Umesh Mohe Nikhil
Dagdu Patil Nilesh
Prabhakar Malpure Pankaj
Venkatsubramanian Tarur Radharkrishnan
Shekhawat Rakesh
Satyanarayan Zawar Sagar
Original Assignee
Usv Ltd
Usv Private Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Usv Ltd, Usv Private Ltd filed Critical Usv Ltd
Publication of BRPI0919827A2 publication Critical patent/BRPI0919827A2/pt
Publication of BRPI0919827A8 publication Critical patent/BRPI0919827A8/pt
Publication of BRPI0919827B1 publication Critical patent/BRPI0919827B1/pt
Publication of BRPI0919827B8 publication Critical patent/BRPI0919827B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol

Abstract

processo aperfeiçoado para peguilação de proteínas. a presente invenção refere-se a um processo para aumentar o rendimento da reação de peguilação de r-meti-iug-csf compreendendo conjugar r-metihug a um peg aldeido em uma porção amina livre na extremidade n terminal da g-csf na presença de um agente redutor em uma solução de tampão de´peguilação compreendendo um poliol tendo a fórmula cnh2n+2on onde varia de 3 a 6 ou um carboidrato, ou um derivado do mesmo varia na faixa de 0,1% a 10% p/p.
BRPI0919827A 2008-10-20 2009-05-04 processos para aumentar o rendimento de uma reação de peguilação de r-methug-csf processo para a produção em escala grama de peg- r-methug-csf BRPI0919827B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2261MU2008 2008-10-20
PCT/IN2009/000262 WO2010089756A2 (en) 2008-10-20 2009-05-04 An improved process for pegylation of proteins

Publications (4)

Publication Number Publication Date
BRPI0919827A2 BRPI0919827A2 (pt) 2016-02-10
BRPI0919827A8 BRPI0919827A8 (pt) 2018-04-17
BRPI0919827B1 BRPI0919827B1 (pt) 2020-04-07
BRPI0919827B8 true BRPI0919827B8 (pt) 2021-05-25

Family

ID=42542457

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0919827A BRPI0919827B8 (pt) 2008-10-20 2009-05-04 processos para aumentar o rendimento de uma reação de peguilação de r-methug-csf processo para a produção em escala grama de peg- r-methug-csf

Country Status (7)

Country Link
US (1) US8586710B2 (pt)
EP (1) EP2337794B1 (pt)
BR (1) BRPI0919827B8 (pt)
CA (1) CA2741209C (pt)
MX (1) MX2011004195A (pt)
RU (1) RU2472806C1 (pt)
WO (1) WO2010089756A2 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014176309A1 (en) 2013-04-23 2014-10-30 Nizyme, Inc. Methods and compositions for treating diseases
US20200237923A1 (en) * 2015-10-14 2020-07-30 The Johns Hopkins University Protein bioconjugation method
USD849464S1 (en) 2017-09-19 2019-05-28 Whirlpool Corporation Coffee maker
EP3902820A2 (en) * 2018-12-28 2021-11-03 Coherus Biosciences, Inc. Process for producing, isolating, and purifying modified recombinant proteins

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0401384B1 (en) * 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
AU9558901A (en) 2000-10-05 2002-04-15 Ares Trading Sa Regioselective liquid phase pegylation
CN101163506B (zh) * 2004-12-27 2012-09-26 巴克斯特国际公司 聚合物-von Willebrand因子偶联物
KR101400105B1 (ko) * 2006-07-25 2014-06-19 리폭센 테크놀로지즈 리미티드 Ｎ-말단 폴리시알화
WO2008051383A2 (en) * 2006-10-19 2008-05-02 Amgen Inc. Use of alcohol co-solvents to improve pegylation reaction yields
TW200836761A (en) 2006-11-09 2008-09-16 Novo Nordisk As N-terminal pegylated prolactin receptor molecules

Also Published As

Publication number Publication date
US20110196134A1 (en) 2011-08-11
EP2337794A2 (en) 2011-06-29
EP2337794B1 (en) 2013-07-31
BRPI0919827A2 (pt) 2016-02-10
MX2011004195A (es) 2011-09-27
BRPI0919827A8 (pt) 2018-04-17
WO2010089756A2 (en) 2010-08-12
WO2010089756A3 (en) 2010-12-16
US8586710B2 (en) 2013-11-19
RU2011120170A (ru) 2012-11-27
CA2741209A1 (en) 2010-08-12
BRPI0919827B1 (pt) 2020-04-07
RU2472806C1 (ru) 2013-01-20
CA2741209C (en) 2016-12-20

Similar Documents

Publication Publication Date Title
BRPI0905080B8 (pt) composição de sulfoalquil éter ciclodextrina (sae-cd), processos para preparar uma composição de sulfoalquil éter ciclodextrina (sae-cd), processo para preparar uma composição e produto
BR122017021516B8 (pt) processo de preparação de uma estrutura de cristal de solvato de (s)-propileno glicol de fórmula ia
BR112012008924A2 (pt) derivado de glicosídeo e usos do mesmo
MX2010006224A (es) Composicion de engomado para lana mineral que comprende un monosacarido y/o un polisacarido y un acido policarboxilico organico, y productos aislantes obtenidos.
ITRM20080636A1 (it) Procedimento per la produzione di derivati funzionalizzati dell acido ialuronico e relativi idrogeli.
BR112012009053A2 (pt) derivado de glicosídeos e usos do mesmo
AU2010230585A8 (en) Autotaxin inhibitors
BRPI0508561A (pt) 3-'4-heterociclil-1,2,3-triazol-1-il-n-aril-benzamidas como inibidores da produção de citocinas para o tratamento de doenças inflamatórias crÈnicas
ATE453670T1 (de) Acrylierte hyaluronsäure
BRPI0919827B8 (pt) processos para aumentar o rendimento de uma reação de peguilação de r-methug-csf processo para a produção em escala grama de peg- r-methug-csf
EA201170591A1 (ru) Композиции и способы для ингибирования экспрессии транстиретина
BRPI0810431A8 (pt) Processo para utilização aperfeiçoada do potencial de produção de plantas transgênicas
BR112012012947B8 (pt) sal de hemitartarato e composição farmacêutica compreendendo o mesmo
BR112014004219A2 (pt) pirano[3,2-d][1,3]tiazol como inibidores de glicosidase
BR112015004501A2 (pt) derivado de ácido hialurônico tendo aminoácidos e grupos esterila introduzidos no mesmo
ITRM20050344A1 (it) Sali o complessi di sostanze metil-donatrici con acido fitico o suoi derivati e relativo metodo di sintesi.
MX2012003726A (es) Conjugacion de polisacaridos capsulares de tipo 5 y de tipo 8 de staphylococcus aureus.
NZ593882A (en) Process for the synthesis of l-fucosyl di- or oligosaccharides and novel 2,3,4 tribenzyl-fucosyl derivatives intermediates thereof
WO2008087642A3 (en) Nucleic acid constructs and methods for specific silencing of h19
ATE442153T1 (de) Zusammensetzungen für die verbesserung der darmgesundheit und der tierischen leistung enthaltend beta-glucans and alfa-fucans
UA98180C2 (ru) Кислотный полисахарид, способы его получения, местная композиция и ее применение
BR112012006674A2 (pt) processo para a inibição ou eliminação da formação de incrustações durante a produção de ácido fosfórico em um processo úmido
SI1831239T1 (sl) Postopek za pripravo gamma laktona hidroksi beta beta beta beta bismetilen alfa pregn en on karboksilne kisline in ključniintermediati za ta postopek
CY1110662T1 (el) Απαλλαγμενοι απο πηκτωματα βλαστοι λιναριου και το παραπροϊον τους, καθως και η παραγωγη και η εφαρμογη τους
ITMI20051085A1 (it) Metodo di purificazione del cefotetan

Legal Events

Date Code Title Description
B15K Others concerning applications: alteration of classification

Ipc: C07K 14/535 (2006.01), A61K 47/60 (2017.01)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25D Requested change of name of applicant approved

Owner name: USV PRIVATE LIMITED (IN)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 07/04/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 04/05/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 14A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2721 DE 28-02-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.